# Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer

> **NCT04780568** · PHASE1 · RECRUITING · sponsor: **Ohio State University Comprehensive Cancer Center** · enrollment: 24 (estimated)

## Conditions studied

- Metastatic Lung Non-Small Cell Carcinoma
- Stage IV Lung Cancer AJCC v8
- Stage IVA Lung Cancer AJCC v8
- Stage IVB Lung Cancer AJCC v8

## Interventions

- **DRUG:** Osimertinib
- **DRUG:** Tegavivint
- **PROCEDURE:** Echocardiography Test
- **PROCEDURE:** Multigated Acquisition Scan
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** FDG-Positron Emission Tomography
- **PROCEDURE:** Biospecimen Collection

## Key facts

- **NCT ID:** NCT04780568
- **Lead sponsor:** Ohio State University Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-01-18
- **Primary completion:** 2026-07-31
- **Final completion:** 2029-07-31
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04780568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04780568, "Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT04780568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*